{"id":6650,"date":"2024-11-21T13:59:54","date_gmt":"2024-11-21T12:59:54","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=6650"},"modified":"2025-04-28T21:41:32","modified_gmt":"2025-04-28T19:41:32","slug":"saffron-103-a-phase-ib-study-of-sitravatinib-plus-tislelizumab-in-anti-pd-l1-refractory-resistant-advanced-melanoma","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/saffron-103-a-phase-ib-study-of-sitravatinib-plus-tislelizumab-in-anti-pd-l1-refractory-resistant-advanced-melanoma\/","title":{"rendered":"SAFFRON-103: a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory\/resistant advanced melanoma\u00a0"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-6650","publication","type-publication","status-publish","hentry","disease_state-melanoma","molecule-tislelizumab"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/6650","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6650"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6650"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}